For the Inventor, By the Inventor

Enter assignee name

Andover, MA, United States of America

Deuterx, LLC

USPTO Granted Patents = 23

% Expired Patents = 8.7

CIPO Patents = 1

EPO Patents = 3

Forward Citations = 358

Loading Chart...

Loading Chart...

5 inventors (with patents filed for the assignee):

Sheila DeWitt (14 out of 21 patents)

Anthony W Czarnik (6 out of 32 patents)

Vincent Jacques (5 out of 30 patents)

4. Leonardus H T Van Der Ploeg (2 out of 32 patents)

5. William Perrault (1 out of 1 patent)

6. Leonardus Van Der Ploeg (4 patents)

7. Sheila Dewitt (0 patent)

23 patents: Sort by Forward Citations

1. 12180137 - Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereof (2024-12-31),

2. 11535603 - Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same (2022-12-27),

3. 11491156 - 3-(substituted-4-oxoquinazolin-3(4)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2022-11-08),

4. 11040925 - 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2021-06-22),

5. 10555946 - 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2020-02-11),

6. 10202316 - 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2019-02-12),

7. 10189858 - Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same (2019-01-29),

8. 10188639 - Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone (2019-01-29),

9. 9925175 - Deuterium-enriched pioglitazone (2018-03-27),

10. 9913845 - 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2018-03-13),

11. 9833445 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2017-12-05),

12. 9809603 - Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same (2017-11-07),

13. 9732031 - Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion (2017-08-15),

14. 9540340 - [object Object] (2017-01-10),

15. 9416117 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2016-08-16),

Company Overview

Deuterx, LLC, based in Andover, MA, specializes in the development of advanced biopharmaceuticals, focusing on innovative therapies that leverage deuterated compounds. The company is dedicated to enhancing drug efficacy and safety through its proprietary technology, which modifies molecular structures to improve pharmacological properties. With a commitment to research and development, Deuterx aims to address unmet medical needs across various therapeutic areas, contributing to the advancement of healthcare solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

23 Patents

#13 in Andover, MA

#869 in Massachusetts

#14,438 in US

#27,714 in the World

Andover, MA, United States of America

Deuterx, LLC

Forward Citations = 358

5 inventors:

Sheila DeWitt (14 out of 21 patents)

Anthony W Czarnik (6 out of 32 patents)

Vincent Jacques (5 out of 30 patents)

4. Leonardus H T Van Der Ploeg (2 out of 32 patents)

5. William Perrault (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Deuterx, LLC. Retrieved from https://idiyas.com/company/deuterx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…